U.S. Health Secretary Robert F. Kennedy Jr. has named eight new members to the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), following the abrupt dismissal of all 17 prior members. The newly appointed panel includes several figures known for expressing skepticism about vaccines, particularly mRNA technology.
Among the new appointees is Robert Malone, a vocal critic of mRNA COVID-19 vaccines and an ally of Kennedy’s "Make America Healthy Again" movement. Other members include Joseph Hibbeln, Martin Kulldorff, Retsef Levi, Cody Meissner, James Pagano, Vicky Pebsworth, and Michael Ross—some of whom have ties to prior CDC or FDA vaccine panels, while others have promoted views critical of current vaccination practices.
Kennedy, who has long challenged vaccine safety despite scientific consensus, claimed the former panel had conflicts of interest, although he did not provide specific evidence. He emphasized the reshuffle was meant to “restore public trust in vaccine science.”
The new ACIP members will participate in the committee’s June 25–27 meeting, where decisions are expected on vaccine recommendations for flu shots and the 2025–26 COVID-19 boosters. The meeting agenda has yet to be released.
The move sparked market reactions: Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) shares dipped slightly, while Novavax (NASDAQ:NVAX), which produces a non-mRNA COVID-19 vaccine, saw a marginal rise.
Concerns remain about the vetting process for the new members. Some, like Pebsworth and Meissner, have served on FDA advisory committees, while others, such as Levi and Kulldorff, have made controversial statements questioning mRNA vaccine safety.
Despite FDA confirmation that mRNA vaccines are safe and effective, Kennedy’s overhaul has intensified the national debate on vaccine policy and public health strategy.


Putin Concludes High-Level Talks With Trump Envoy on Ending Ukraine Conflict
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Intel Boosts Malaysia Operations with Additional RM860 Million Investment
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Australia Progresses AUKUS Review as U.S. Affirms Strong Support
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Amazon Debuts “Amazon Now” for 30-Minute Ultrafast Grocery Delivery
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
UN Chief Says Gaza Operation “Fundamentally Wrong” as Concerns Over War Crimes Grow
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 



